menu
    • menu
    [{"orgOrder":0,"company":"AiCuris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pritelivir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ Not Applicable"},{"orgOrder":0,"company":"AiCuris","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AiCuris","amount2":0.22,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.22,"dosageForm":"","sponsorNew":"AiCuris \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AiCuris \/ Royalty Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by AiCuris

    Menu

    AiCuris

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AiCuris

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Letermovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Royalty Pharma

                            Deal Size : $220.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Royalty Pharma Acquires Partial Royalty Interest On Prevymis™ (Letermovir) From Aicuris Anti-Infective Cures...

                            Details : Prevymis™ (letermovir) was approved by the US FDA in 2017 and by the EMA and Japan’s PMDA in 2018 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at high ri...

                            Brand Name : Prevymis

                            Molecule Type : Small molecule

                            Upfront Cash : $220.0 million

                            June 09, 2020

                            Lead Product(s) : Letermovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Royalty Pharma

                            Deal Size : $220.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AiCuris

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AiCuris Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir to Treat HSV Infections in Immunoc...

                            Details : Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible . Company is now preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 05, 2020

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth